DGAP-News: amp biosimilars AG / Key word(s): Change of Personnel2016-06-28 / 08:30The issuer is solely responsible for the content of this announcement.---------------------------------------------------------------------------amp biosimilars announces Klaus K. Wilgenbus as new CEO- Experienced industry executive to start as new CEO on July 1 - Founding CEO Marc W. Hentz steps down in a planned succession moveHamburg, Germany, June 28 2016 - amp biosimilars AG (ISIN: DE000A0SMU87), acompany specializing in the development of high-quality biosimilars, todayannounced that Klaus K. Wilgenbus will lead the firm as the new CEO fromJuly 1, 2016.In 2014 Klaus Wilgenbus retired as Corp. Senior VP Business DevelopmentLicensing and Strategy from Boehringer Ingelheim (BI). During his 18 yeartenure at BI he held various positions covering Business Development, R&D,innovation management, corporate and commercial strategy, andorganizational development. Under his leadership BI has entered into morethan 200 strategic transactions incl. R&D collaborations, globalco-promotion and co-marketing alliances, JV's and merger and acquisitionswith business partners from North-America, EU and Asia. Klaus Wilgenbusalso served on various boards such as Karolinska Development AB (SolnaSweden), Actimis Inc. (San Diego) and Boehringer Ingelheim Deutschland GmbH& Co KG and represented BI at the Board of (US) BIO. After 2014 KlausWilgenbus served as interim-CEO at Karolinska Development AB and advised asindependent consultant small to mid sized biotech companies and lifesciences investors  in the areas of corporate strategy, fundraising andbusiness transactions. Wilgenbus was trained as a physician in Germany andthe US and holds an MD from RWTH Aachen."It's an exciting time to be joining amp biosimilars, with the company'sproduct and deal pipeline growing rapidly" said Wilgenbus. "I look forwardto joining the amp team in order to advance the development of newhigh-quality therapies for patients in both the pharmerging and theregulated markets, the primary focus of the work at amp."Founding CEO Dr. Marc W. Hentz retires from the post in a plannedsuccession move. "I am excited that we can implement our plan to attract anexperienced industry leader to join amp for its next phase of corporatedevelopment. The Board's appointment of Klaus Wilgenbus is a testimony toour success and strategic direction, and I sincerely congratulate him.Klaus is an experienced biopharma executive and an outstanding dealmakerwhose skill-set will directly contribute to the firm's future growth path.As a founder and shareholder I am excited about his future impact on thecompany and will continue to support amp in any advisory or other capacityrequired."Chairman of amp Supervisory Board Dr. Thomas Zimmer comments: "With KlausWilgenbus we have identified a leading pharma executive who brings atremendous wealth of pharma and biotech knowhow to amp biosimilars AG. Theaddition of his business acumen enhances our ability to deliver high-valuebiosimilars for the future. I thank Marc Hentz for his 2 years ofsuccessful leadership in building the company and securing its first outlicensing deals, and I am sure that Klaus Wilgenbus will ensure thecontinued expansion of our position as leader in biosimilar development."About amp biosimilars AG: amp biosimilars AG develops high quality biosimilars to meet growing demandon global therapeutic markets and is one of the most innovative and dynamicbiosimilar companies in Europe. The company is headquartered in Hamburg andrun by a team of leading industry experts. The development of a widevariety of biosimilars will provide patients around the world with accessto life-improving and life-saving therapies. The combination of a researchplatform with state-of-the-art analytics, process technology and clinicalexpertise as well as regulatory know-how, makes amp biosimilars AG one ofthe leading companies for biosimilar development and marketing. Thanks toan international network of leading pharmaceutical companies, ampbiosimilars AG also has direct access to the strongest growing markets inthe world. With this approach amp biosimilars AG has a key position in oneof the fastest growing life science markets in the near future. ampbiosimilars AG has been listed on the Munich Stock Exchange since April 1,2015. For more information please go to www.ampbiosimilars.com.Contact:Fabian LorenzFlorenz KommunikationT: +49 211 29831588E-mail: lorenz@florenz-kommunikation.de---------------------------------------------------------------------------2016-06-28 Dissemination of a Corporate News, transmitted by DGAP - aservice of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Archive at www.dgap.de---------------------------------------------------------------------------     Language:    English                                     Company:     amp biosimilars AG                                       Am Kaiserkai 1                                           22391 Hamburg                                            Germany                                     Phone:       +49 40 80 80 74 760                         Internet:    http://www.ampbiosimilars.com               ISIN:        DE000A0SMU87                                WKN:         A0SMU8                                      Listed:      Regulated Unofficial Market in Munich             End of News    DGAP News Service  
Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.